Benavides et al. "Optimisation" of tocilizumab in GCA. Dose decreased or interval increased. 231 patients. Sustained remission 78.2% optimised group (vs 66.7%). @rheumnow #ACR22 Abstr#0474 https://t.co/jPRy4RjfJA https://t.co/b1CP8pFwhJ
Links:
Utility of Optimization of Tocilizumab Therapy in Giant Cell Arteritis: A Multi…
https://acrabstracts.org/abstract/utility-of-optimization-of-tocilizumab-therap…
12-11-2022
